Online inquiry

IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4508MR)

This product GTTS-WQ4508MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CXCL10 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001565.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3627
UniProt ID P02778
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ4508MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ748MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AAB-001
GTTS-WQ50MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 2857916
GTTS-WQ7598MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ13251MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-05335810
GTTS-WQ13245MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-05335810
GTTS-WQ12986MR IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PEG sTNF-RI
GTTS-WQ1673MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ACZ885
GTTS-WQ9307MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMP-321
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW